Noradrenergic Augmentation of SSRI [selective serotonin reuptake inhibitor] therapy in patients with depression unresponsive or incompletely responsive to SSRI monotherapy

Trial Profile

Noradrenergic Augmentation of SSRI [selective serotonin reuptake inhibitor] therapy in patients with depression unresponsive or incompletely responsive to SSRI monotherapy

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Jan 2010

At a glance

  • Drugs Atomoxetine; Sertraline
  • Indications Major depressive disorder
  • Focus Pharmacogenomic; Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 30 Jan 2010 Results were published in Psychiatry Research.
    • 18 Jun 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top